Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland maintains a Buy rating on Cross Country Healthcare (NASDAQ:CCRN) but lowers the price target from $21 to $19.

May 02, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst maintains a Buy rating on Cross Country Healthcare but lowers the price target from $21 to $19.
The adjustment in price target by Benchmark reflects a nuanced view on Cross Country Healthcare's future performance. While the Buy rating indicates continued confidence in the company's fundamentals, the reduction in price target suggests a recalibration of expectations, possibly due to market conditions or company-specific factors not detailed in the article. This could lead to short-term price volatility as investors reassess their expectations based on the new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100